​

Enveric Biosciences Stock (NASDAQ:ENVB)

ForecastOwnershipFinancialsChart
Enveric Biosciences by TradingView

Previous Close

$0.63

52W Range

$0.56 - $8.25

50D Avg

$0.98

200D Avg

$1.42

Market Cap

$1.52M

Avg Vol (3M)

$507.80K

Beta

0.29

Div Yield

-

ENVB Company Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5

IPO Date

May 04, 2015

Website

ENVB Performance

ENVB Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-9.63M$-16.45M$-27.42M
Net Income$-9.57M$-17.29K$-18.47M
EBITDA$-9.25M$-16.85M$-19.63M
Basic EPS$-19.04$-8.09$-12.77
Diluted EPS$-19.04$-8.09$-12.77

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
ASBPAspire Biopharma Holdings, Inc.
ZVSAZyVersa Therapeutics, Inc.
CARMCarisma Therapeutics, Inc.
SPRCSciSparc Ltd.
JSPRJasper Therapeutics, Inc.
CDTCDT Equity Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
REVBRevelation Biosciences, Inc.
SLRXSalarius Pharmaceuticals, Inc.